Literature DB >> 26316245

The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk.

Valerie A Flores1, Hugh S Taylor2.   

Abstract

Estrogen and P treatment results in greater risk of breast cancer than placebo. Treatment with estrogen alone does not increase the risk of breast cancer, may be used by women who have had a hysterectomy, and may even result in a decreased risk of breast cancer. Continued research seeks to improve the understanding of the interplay between estrogen and progestogens that predispose to adverse effects on breast tissue. Caution over this hypothesized benefit is warranted until it is substantiated by data on the incidence of breast cancer in tissue selective estrogen complex users.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Estrogens; Hormone therapy; Menopause; Progestogen

Mesh：

Year:  2015        PMID： 26316245      PMCID： PMC4555991          DOI： 10.1016/j.ecl.2015.05.007

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  87 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

2.  Progesterone action in normal mouse mammary gland.

Authors:  S Wang; L J Counterman; S Z Haslam
Journal:  Endocrinology       Date:  1990-11       Impact factor: 4.736

3.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

Authors:  Marcia L Stefanick; Garnet L Anderson; Karen L Margolis; Susan L Hendrix; Rebecca J Rodabough; Electra D Paskett; Dorothy S Lane; F Allan Hubbell; Annlouise R Assaf; Gloria E Sarto; Robert S Schenken; Shagufta Yasmeen; Lawrence Lessin; Rowan T Chlebowski
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

4.  Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study.

Authors:  Tanmai Saxena; Eunjung Lee; Katherine D Henderson; Christina A Clarke; Dee West; Sarah F Marshall; Dennis Deapen; Leslie Bernstein; Giske Ursin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-10       Impact factor: 4.254

5.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.

Authors:  Catherine M Kelly; David N Juurlink; Tara Gomes; Minh Duong-Hua; Kathleen I Pritchard; Peter C Austin; Lawrence F Paszat
Journal:  BMJ       Date:  2010-02-08

6.  Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.

Authors:  Heli Lyytinen; Eero Pukkala; Olavi Ylikorkala
Journal:  Obstet Gynecol       Date:  2009-01       Impact factor: 7.661

7.  Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.

Authors:  Yayun Liang; Cynthia Besch-Williford; Rolf A Brekken; Salman M Hyder
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Authors:  Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

10.  Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study.

Authors:  Elizabeth E Sweeney; Ping Fan; V Craig Jordan
Journal:  Cancer Res       Date:  2014-10-10       Impact factor: 12.701
View more
  3 in total

Review 1.  Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.

Authors:  Flavia Zita Francies; Rodney Hull; Richard Khanyile; Zodwa Dlamini
Journal:  Am J Cancer Res       Date:  2020-05-01       Impact factor: 5.942

2.  Hormone therapy use and breast tissue DNA methylation: analysis of epigenome wide data from the normal breast study.

Authors:  Sophia Harlid; Zongli Xu; Erin Kirk; Lauren E Wilson; Melissa A Troester; Jack A Taylor
Journal:  Epigenetics       Date:  2019-03-01       Impact factor: 4.528

3.  Identification of Candidate Genes in Breast Cancer Induced by Estrogen Plus Progestogens Using Bioinformatic Analysis.

Authors:  Yu Deng; He Huang; Jiangcheng Shi; Hongyan Jin
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.